LymeNet Home LymeNet Home Page LymeNet Flash Discussion LymeNet Support Group Database LymeNet Literature Library LymeNet Legal Resources LymeNet Medical & Scientific Abstract Database LymeNet Newsletter Home Page LymeNet Recommended Books LymeNet Tick Pictures Search The LymeNet Site LymeNet Links LymeNet Frequently Asked Questions About The Lyme Disease Network LymeNet Menu

LymeNet on Facebook

LymeNet on Twitter

Tax deductible

The Lyme Disease Network receives a commission from for each purchase originating from this site.

When purchasing from, please
click here first.

Thank you.

LymeNet Flash Discussion
Dedicated to the Bachmann Family

LymeNet needs your help:
LymeNet fund drive

The Lyme Disease Network is a non-profit organization funded by individual donations.
In the United States, your donations are tax deductible.

LymeNet Flash Post New Topic  New Poll  Post A Reply
my profile | directory login | register | search | faq | forum home

  next oldest topic   next newest topic
» LymeNet Flash » Questions and Discussion » General Support » Esketamin (Spravato) anti-d Rx Risks questioned

 - UBBFriend: Email this page to someone!    
Author Topic: Esketamin (Spravato) anti-d Rx Risks questioned
Honored Contributor (25K+ posts)
Member # 12673

Icon 1 posted      Profile for Keebler         Edit/Delete Post   Reply With Quote 
A new anti-depression drug that is now on the market, and even some in VA can still get it. No matter that six people died in the only - one - small trial (all lived who received the placebo).

Experts question Esketamine (Spravato) safety and effectiveness.

By Peter Cary, reporter - Public - June 21, 2019


A Department of Veterans Affairs panel has pushed back against efforts to rush a controversial anti-depression drug into use for its patients, voting not to include the drug, Spravato, on its list of drugs available through prescription at its pharmacies. . . .

. . . The “No” vote, which occurred Thursday, is likely to be a blow to Janssen Pharmaceuticals, the drug’s maker, and its parent, Johnson & Johnson, which hopes Spravato will be a $600 million blockbuster by 2022. . . .

. . . Despite claims by Janssen and the FDA that the drug is fast and effective, some psychiatrists said they had concerns about balancing the drug’s effectiveness against its dangers.

Questions have been raised about the protocols of the drug’s clinical trials, the FDA’s speedy approval process,

and the known effects of the drug -

– dissociation (an out of body experience), dizziness, sedation, and heightened blood pressure.

In the drug’s trials, three people who had taken it committed suicide and three others died — as opposed to none on placebos — though the FDA and Janssen said there was no evidence the drug and the deaths were linked. . . .

. . . The FDA approved the drug March 5, setting aside its usual rules for anti-depressant approval and accepting one short-term trial instead of the usual two. . . .

[Full article at link above. So many more key details.]

Posts: 47698 | From Tranquil Tree House in my dreams | Registered: Jul 2007  |  IP: Logged | Report this post to a Moderator

Quick Reply

HTML is not enabled.
UBB Code is enabled.

Instant Graemlins

Post New Topic  New Poll  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:

Contact Us | LymeNet home page | Privacy Statement

© 1993-2019 The Lyme Disease Network of New Jersey, Inc.
All Rights Reserved.
Use of the LymeNet Site is subject to the Terms and Conditions.

Powered by UBB.classic™ 6.7.3

Home | Flash Discussion | Support Groups | On-Line Library
Legal Resources | Medical Abstracts | Newsletter | Books
Pictures | Site Search | Links | Help/Questions
About LymeNet | Webmaster